Clinical Study | Office of Clinical Research

A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Relapsing Multiple Sclerosis

Posted Date: Oct 29, 2020

Investigator: Lawrence Goldstick
Specialties: Multiple Sclerosis, Neurology
Type of Study: Drug

A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

Criteria:

Patients With Relapsing Multiple Sclerosis Who Have Never Used Ocrelizumab

Keywords:

Ocrelizumab, Ocrevus, Multiple Sclerosis

For More Information:

Mikayla Hoeferlin
937-535-5012
hoefermj@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List